Thu, Apr 17, 2014, 7:55 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

slumdawg2011 77 posts  |  Last Activity: Apr 16, 2014 11:34 AM Member since: May 2, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    IMGN started at BUY

    by bioimmunomabman Apr 16, 2014 9:28 AM
    slumdawg2011 slumdawg2011 Apr 16, 2014 11:34 AM Flag

    Looks like Canaccord is the designated analyst to make the official announcement of the start of biotech pps reversal, buying in by hedgies, and the beginning of a new pumping cycle.

  • Reply to

    Plunges afresh

    by sorohoho Apr 11, 2014 2:50 PM
    slumdawg2011 slumdawg2011 Apr 14, 2014 10:33 PM Flag

    Hedgies don't seem to be done driving biotech down. They really want to buy back dirt cheap before they drive SP up again by ASCO. These people should be locked up with Madoff. Thrown in Steve Cohen there, too, and the other big fishes swimming in dark pools.

  • Reply to

    Can anyone explain the reason for the price drop?

    by opto7825 Apr 14, 2014 11:28 AM
    slumdawg2011 slumdawg2011 Apr 14, 2014 6:13 PM Flag

    Manipulators not yet done with biotech beat up. This may last all through April.

  • Reply to

    Pleeeeassssse....

    by slumdawg2011 Apr 11, 2014 11:08 AM
    slumdawg2011 slumdawg2011 Apr 11, 2014 2:38 PM Flag

    I think NVAX has good vaccine technology, but just like many biotechs, it is the market cap that makes it tricky to decide on how good a buy most of these biotechs are. What was that Eu vaccine company that got bought a few years back by JNJ? Crucell! Amazing how I was having a hard time recalling, then just pulled it out from deep recesses of my cluttered brain by the time I typed the question mark. I don't know how much Crucell was bought for.

  • slumdawg2011 by slumdawg2011 Apr 11, 2014 11:08 AM Flag

    Make the bleeding stop! My biotech portfolio is more leaky than wet AMD! I'm getting retinal detachment from looking at the falling stock prices! I already had to sell some of my LPTN.

    Any good stock for hemophilia? I think SGMO will own hemophilia many years from now with their gene editing technology, but I believe it is overpriced at this time. For now the X-factors will have to do.

  • Reply to

    Good news and bad news

    by bioimmunomabman Apr 9, 2014 9:35 AM
    slumdawg2011 slumdawg2011 Apr 9, 2014 2:49 PM Flag

    I believe we'll get more clinical data from the other partnered drugs this year. If Kadcyla sales don't show signs of slowing down, I'll say we might get back to 2013 highs at least.

  • Reply to

    Good news and bad news

    by bioimmunomabman Apr 9, 2014 9:35 AM
    slumdawg2011 slumdawg2011 Apr 9, 2014 11:59 AM Flag

    Btechs moving up. For real, or another head fake? I believe, there's usually a head fake after AACR, followed by profit taking again before the ASCO rise.

  • Reply to

    853 dosing

    by bioimmunomabman Apr 8, 2014 4:55 PM
    slumdawg2011 slumdawg2011 Apr 8, 2014 5:58 PM Flag

    If you're late stage, do you really care about temporary blindness, or even partial blindness for that matter? Should the trials focus perhaps on advance stage patients with few options?

    Are there no folate eye drops that they could use to saturate the eye folate receptors before they administer 853? They probably have thought about that.

  • Reply to

    AACR

    by slumdawg2011 Apr 6, 2014 9:13 AM
    slumdawg2011 slumdawg2011 Apr 7, 2014 5:36 PM Flag

    No press release today? What's wrong with your IMGN mgmt, Mabman?

  • Reply to

    QCOR 17.5MM shares short

    by bioimmunomabman Apr 7, 2014 8:44 AM
    slumdawg2011 slumdawg2011 Apr 7, 2014 10:24 AM Flag

    That should get most biotechs in the green today. Just the break we need. Even filthy Ranbaxy got bought.

  • slumdawg2011 by slumdawg2011 Apr 6, 2014 9:13 AM Flag

    Will cancer company updates stem the biotech bleeding? I'll be delighted if the cancer stocks at least stay in the green come Monday.

    Sunday, April 6:
    • Abstract #667 “IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression” (1:00-5:00pm PT, Poster Section 28, Poster Board Number 24)

    Monday, April 7:
    • Abstract #1618 “New peptide-linked anilino-maytansinoid antibody-drug conjugates (ADCs) for the treatment of cancer” (8:00am-12:00pm PT, Poster Section 27, Poster Board Number 1)
    • Abstract #2644 “Antibody-drug conjugates (ADCs) with a novel DNA-alkylating agent, DGN462, are highly potent in vitro and in vivo against human cancer models” (1:00-5:00pm PT, Poster Section 31, Poster Board Number 5)

    Tuesday, April 8:
    • Abstract #4513 “IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors” (1:00-5:00pm PT, Poster Section 29, Poster Board Number 23)
    • Abstract #4641 “Development of modified dosing approaches to achieve specific pharmacokinetic (PK) objectives in the first-in-human phase I clinical trial of IMGN853, a folate receptor α-targeting antibody drug conjugate” (1:00-5:00pm PT, Poster Section 35, Poster Board Number 35)

  • Reply to

    Why is the biotech sky falling again?

    by slumdawg2011 Apr 3, 2014 11:23 AM
    slumdawg2011 slumdawg2011 Apr 4, 2014 6:19 PM Flag

    Combination of man factors. The GILD issue, Crimea, EXEL bad news, and today the HALO bad news. All are shaking biotech longs, and this prolonged pain in the sector is self-propagating because of margin calls. If biotech does not recover on Monday with buyout or other good news, I may have to sell again. I'm afraid manipulators will wait until ASCO abstract release to start pushing biotechs up again. The pattern is not entirely new for this time of year. It just seems much longer this time.

    Bad thing is I just added to my IMGN shares when it dipped to 14.30. I may have to resell at a loss.

  • Overweight?

  • Reply to

    IMGN is like my relatives

    by jiarealty Apr 1, 2014 4:44 PM
    slumdawg2011 slumdawg2011 Apr 2, 2014 10:39 AM Flag

    I buried my money in my backyard when I buried my mother-in-law!

    Wait! That's not right! I threw my money overboard in the ocean one dark stormy night. Boy, was she heavy!

  • slumdawg2011 by slumdawg2011 Apr 1, 2014 8:41 PM Flag

    Very interesting since most of my biotechs got slammed really hard with rampaging Putin and the Dear Gilead letter. There's something going on under the turbulent biotech waters. Or maybe it's just the missing Malaysian plane.

  • Reply to

    Wow, what a sick buying opportunity

    by smelky_kid Mar 28, 2014 3:54 PM
    slumdawg2011 slumdawg2011 Mar 29, 2014 3:03 PM Flag

    The pig got fattened on margin, and is now losing all that extra fat. I haven't sold my SGEN since I don't need to, but getting punished on GILD and EXEL. It's easy to get reckless once you have more play money around. I promise I'll play safer next time, hawk. Oddly enough, who would have thought GILD is a reckless play with the S100 price targets that analyst are throwing around.

  • Reply to

    Wow, what a sick buying opportunity

    by smelky_kid Mar 28, 2014 3:54 PM
    slumdawg2011 slumdawg2011 Mar 28, 2014 4:25 PM Flag

    You know biotechs are being punished when HALO reports a product approval and it still finishes in the red!

  • Reply to

    Wow, what a sick buying opportunity

    by smelky_kid Mar 28, 2014 3:54 PM
    slumdawg2011 slumdawg2011 Mar 28, 2014 4:02 PM Flag

    Buying opportunity indeed if you have money to spare. With biotech being crashed for more than 2 weeks now, my biotech portfolio, which has many small caps, is down almost 40% for the year. Margin calls have been driving my selling and most probably others as well. Manipulators seem to have no plans soon of letting up.

  • Reply to

    RA Capital Huge Stakes in Achillion Pharma.

    by macugen_rules Mar 21, 2014 8:04 PM
    slumdawg2011 slumdawg2011 Mar 22, 2014 10:07 PM Flag

    I've been buying more calls, and some stocks. Reasonably price $3 hits for June. Too soon perhaps.

  • Reply to

    ohr has only 2 employees

    by charles_lacy2003 Mar 20, 2014 4:34 PM
    slumdawg2011 slumdawg2011 Mar 22, 2014 7:19 PM Flag

    I disagree, Left-e. I actually enjoy the back and forth discussions. Let's call it intelligent discussions instead of arguments. This is one way we develop intelligent investing decisions. For all you know, you might end up saving some Ohr investors from complete ruin, at the same time join us in LPTN investing. That's why I like Feuerstein even though he's been wrong many times. He at least makes us aware of the bearish points. Other than AF only has good things to say about LPTN.

    I agree though about your statement about Elman's 1 responder. I can't really say that he is an unbiased expert.

    So if there is not much BBB to speak of when a drug is administered to the eye, why don't drug developers just take that route, instead of struggling to find ways to overcome the BBB for IV drugs for neuro disorders?

CLDX
14.24-0.45(-3.06%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.